X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (34) 34
oncology (33) 33
humans (28) 28
female (25) 25
cancer (24) 24
physics, fluids & plasmas (19) 19
middle aged (17) 17
aged (15) 15
ovarian cancer (15) 15
research (14) 14
survival (13) 13
physics, nuclear (12) 12
adult (11) 11
analysis (10) 10
mortality (10) 10
chemotherapy (9) 9
obstetrics & gynecology (9) 9
care and treatment (8) 8
hematology, oncology and palliative medicine (8) 8
male (8) 8
nuclear science & technology (8) 8
oncology, experimental (8) 8
mining & mineral processing (7) 7
ovarian neoplasms - drug therapy (7) 7
ovarian neoplasms - genetics (7) 7
ovarian neoplasms - pathology (7) 7
prognosis (7) 7
aged, 80 and over (6) 6
breast-cancer (6) 6
epidemiology (6) 6
materials science (6) 6
patients (6) 6
brca1 (5) 5
breast cancer (5) 5
carcinoma (5) 5
carcinoma, ovarian epithelial (5) 5
discharges (5) 5
disease-free survival (5) 5
divertor (5) 5
immortal time bias (5) 5
medical research (5) 5
neoplasms, glandular and epithelial - drug therapy (5) 5
optics (5) 5
ovarian neoplasms - metabolism (5) 5
survival analysis (5) 5
tokamak (5) 5
transport (5) 5
animals (4) 4
cisplatin (4) 4
clinical trials (4) 4
databases (4) 4
diagnosis (4) 4
diii-d (4) 4
endocrine system diseases (4) 4
energy confinement (4) 4
genetics (4) 4
gynecologic-oncology-group (4) 4
health aspects (4) 4
health risk assessment (4) 4
impurity transport (4) 4
laser beam welding (4) 4
materials science, multidisciplinary (4) 4
mutation (4) 4
neoadjuvant therapy (4) 4
neoplasm staging (4) 4
neoplasms, glandular and epithelial - pathology (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
obstetrics and gynecology (4) 4
ovarian carcinoma (4) 4
paclitaxel (4) 4
pathway (4) 4
physics, applied (4) 4
poly polymerase (4) 4
population-based (4) 4
risk (4) 4
therapy (4) 4
treatment outcome (4) 4
tumors (4) 4
up-to-date (4) 4
adenocarcinoma (3) 3
adrenergic beta-antagonists - administration & dosage (3) 3
aluminum (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
apoptosis (3) 3
biomarkers (3) 3
cancer patients (3) 3
cancer research (3) 3
cancer survival (3) 3
carcinoma, squamous cell - pathology (3) 3
cell line, tumor (3) 3
cell lung-cancer (3) 3
cohort studies (3) 3
colorectal-cancer (3) 3
dna repair (3) 3
drug therapy (3) 3
empirical-evaluation (3) 3
erosion (3) 3
follow-up studies (3) 3
gene expression (3) 3
gene-expression (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_5
Abstract Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo and was associated with... 
Journal Article
Obstetrical & Gynecological Survey, ISSN 0029-7828, 04/2018, Volume 73, Issue 4, pp. 209 - 210
(Abstracted from Ann Oncol 2018;29(2):431–438)The use of neoadjuvant chemotherapy (NACT) prior to surgical debulking is increasingly used for advanced... 
OBSTETRICS & GYNECOLOGY | Care and treatment | Chemotherapy | Comparative analysis | Methods | Ovarian cancer | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4501 - 4510
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2011, Volume 22, Issue 11, pp. 2403 - 2410
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 137, Issue 2, pp. 216 - 222
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_5
Abstract Background Rucaparib is approved in the European Union and the United States for use as treatment or maintenance for women with ovarian cancer. Here... 
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 2016, Volume 14, Issue 1, p. 83
Journal Article
International Journal of Gynecologic Cancer, ISSN 1048-891X, 09/2019, Volume 29, Issue Suppl 3, p. A1
ObjectivesIn ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo. A prespecified exploratory analysis... 
Journal Article